Abstract
Diagnostic and prognostic capability of Randox Laboratories Ltd Biochip Technology Arrays CKD I and II and AKI array in CKD and AKI patients
Authors – Andrew English1, Sean McCallion1, Eamonn Cooper1, Sebastian Philip2, Ying Kuan3, Mary Jo Kurth4, Kenneth Martin5, Eibhlin McCole5, Ciaran Richardson5, Tony Bjourson1
Affiliations
1. CTRIC, Altnagelvin Hospital campus, Glenshane Road, Derry/Londonderry BT47 6SB
2. LYIT Port Rd, Gortlee, Letterkenny, Co. Donegal, Ireland
3. WHSCT Glenshane Rd, Londonderry BT47 6SB
4. Randox Laboratories Ltd, 55 Diamond Road, Co. Antrim, BT29 4QY
5. Randox Teoranta, Meenmore, Dungloe, Co Donegal F94 TV06
Introduction
Chronic kidney disease (CKD) is defined as a reduction in eGFR < 60mL/min/1.73m2, and is a growing public health problem, with its incidence doubled in the past three decades. The identification of novel biomarkers in clinical practice is crucial to allow earlier diagnosis and improve patient outcomes.
Methods
This study aimed to assess the diagnostic and prognostic capability of commercially available CKD panels in Northern Ireland CKD and AKI patients. In collaboration with Randox Laboratories Ltd we utilised their patented Biochip Array Technology to assess plasma and urine protein expression (Randox Chronic Kidney Disease (CKD) Array I (7-plex) [FABP1, MIP1, sTNFR1, sTNFR2,]; Array II (4-plex) [CRP, Cystatin C, C3a Des Arg, NGAL], Urine AKI Array I [KIM-1, NGAL, Cystatin C, clusterin] at time of recruitment and at 1 year follow-up for CKD patients and 3 month follow up for AKI patients. All patients completed a health and lifestyle questionnaire, consented for access to their electronic care record and provided a blood and urine sample.
Results
Forty-three AKI patients (mean age=61 years; 47% male), 153 CKD patients (mean age=59; 63% male) 52 healthy controls (HC) (mean age=45 year; 65% male) were included in the study. Receiver operating characteristic (ROC) analysis showed that novel combinations of the Randox proteins were best able to distinguish between AKI patients and HC (AUC for plasma=1.0; AUC for urine=0.873), CKD patients and HC (AUC for plasma=0.954; AUC urine=0.736), and AKI and CKD patients (AUC for plasma=0.974; AUC for urine=0.913). ROC analysis for AKI-to-CKD progression (AUC 0.55, n=10) and rapid CKD progression (AUC 0.53, n=19) showed that for this cohort there was no single biomarker or combination with prognostic ability.
Conclusions
Randox Laboratories Ltd CKD Arrays I and II and AKI Array are specific and sensitive for diagnosing both AKI and CKD (~AUC 0.92). Further studies, in a larger cohort with age matched controls, are required to further evaluate the prognostic capability of these biomarkers.
Authors – Andrew English1, Sean McCallion1, Eamonn Cooper1, Sebastian Philip2, Ying Kuan3, Mary Jo Kurth4, Kenneth Martin5, Eibhlin McCole5, Ciaran Richardson5, Tony Bjourson1
Affiliations
1. CTRIC, Altnagelvin Hospital campus, Glenshane Road, Derry/Londonderry BT47 6SB
2. LYIT Port Rd, Gortlee, Letterkenny, Co. Donegal, Ireland
3. WHSCT Glenshane Rd, Londonderry BT47 6SB
4. Randox Laboratories Ltd, 55 Diamond Road, Co. Antrim, BT29 4QY
5. Randox Teoranta, Meenmore, Dungloe, Co Donegal F94 TV06
Introduction
Chronic kidney disease (CKD) is defined as a reduction in eGFR < 60mL/min/1.73m2, and is a growing public health problem, with its incidence doubled in the past three decades. The identification of novel biomarkers in clinical practice is crucial to allow earlier diagnosis and improve patient outcomes.
Methods
This study aimed to assess the diagnostic and prognostic capability of commercially available CKD panels in Northern Ireland CKD and AKI patients. In collaboration with Randox Laboratories Ltd we utilised their patented Biochip Array Technology to assess plasma and urine protein expression (Randox Chronic Kidney Disease (CKD) Array I (7-plex) [FABP1, MIP1, sTNFR1, sTNFR2,]; Array II (4-plex) [CRP, Cystatin C, C3a Des Arg, NGAL], Urine AKI Array I [KIM-1, NGAL, Cystatin C, clusterin] at time of recruitment and at 1 year follow-up for CKD patients and 3 month follow up for AKI patients. All patients completed a health and lifestyle questionnaire, consented for access to their electronic care record and provided a blood and urine sample.
Results
Forty-three AKI patients (mean age=61 years; 47% male), 153 CKD patients (mean age=59; 63% male) 52 healthy controls (HC) (mean age=45 year; 65% male) were included in the study. Receiver operating characteristic (ROC) analysis showed that novel combinations of the Randox proteins were best able to distinguish between AKI patients and HC (AUC for plasma=1.0; AUC for urine=0.873), CKD patients and HC (AUC for plasma=0.954; AUC urine=0.736), and AKI and CKD patients (AUC for plasma=0.974; AUC for urine=0.913). ROC analysis for AKI-to-CKD progression (AUC 0.55, n=10) and rapid CKD progression (AUC 0.53, n=19) showed that for this cohort there was no single biomarker or combination with prognostic ability.
Conclusions
Randox Laboratories Ltd CKD Arrays I and II and AKI Array are specific and sensitive for diagnosing both AKI and CKD (~AUC 0.92). Further studies, in a larger cohort with age matched controls, are required to further evaluate the prognostic capability of these biomarkers.
| Original language | English |
|---|---|
| Publication status | Published - 5 Apr 2022 |
| Event | Center for Personilised Medcine 2022 - Duration: 5 Apr 2022 → 7 Apr 2022 |
Conference
| Conference | Center for Personilised Medcine 2022 |
|---|---|
| Period | 5/04/22 → 7/04/22 |